Literature DB >> 21936584

Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?

Marc C Chamberlain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21936584     DOI： 10.2165/11587880-000000000-00000

Source DB:  PubMed          Journal:  CNS Drugs        ISSN： 1172-7047            Impact factor:   5.749


× No keyword cloud information.
  18 in total

1.  What is the evidence that tumors are angiogenesis dependent?

Authors:  J Folkman
Journal:  J Natl Cancer Inst       Date:  1990-01-03       Impact factor: 13.506

2.  Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system.

Authors:  Victor A Levin; Luc Bidaut; Ping Hou; Ashok J Kumar; Jeffrey S Wefel; B Nebiyou Bekele; Jai Grewal; Sujit Prabhu; Monica Loghin; Mark R Gilbert; Edward F Jackson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-04-01       Impact factor: 7.038

3.  Survival of patients with newly diagnosed glioblastoma treated with radiation and temozolomide in research studies in the United States.

Authors:  Stuart A Grossman; Xiaobu Ye; Steven Piantadosi; Serena Desideri; Louis B Nabors; Myrna Rosenfeld; Joy Fisher
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

Review 4.  Emerging clinical principles on the use of bevacizumab for the treatment of malignant gliomas.

Authors:  Marc C Chamberlain
Journal:  Cancer       Date:  2010-09-01       Impact factor: 6.860

5.  The addition of bevacizumab to standard radiation therapy and temozolomide followed by bevacizumab, temozolomide, and irinotecan for newly diagnosed glioblastoma.

Authors:  James J Vredenburgh; Annick Desjardins; David A Reardon; Katherine B Peters; James E Herndon; Jennifer Marcello; John P Kirkpatrick; John H Sampson; Leighann Bailey; Stevie Threatt; Allan H Friedman; Darell D Bigner; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2011-04-29       Impact factor: 12.531

6.  A phase 2 trial of single-agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas.

Authors:  Jeffrey J Raizer; Sean Grimm; Marc C Chamberlain; M Kelly Nicholas; James P Chandler; Kenji Muro; Steven Dubner; Alfred W Rademaker; Jaclyn Renfrow; Markus Bredel
Journal:  Cancer       Date:  2010-11-15       Impact factor: 6.860

7.  Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma.

Authors:  Wolfgang Wick; Vinay K Puduvalli; Marc C Chamberlain; Martin J van den Bent; Antoine F Carpentier; Lawrence M Cher; Warren Mason; Michael Weller; Shengyan Hong; Luna Musib; Astra M Liepa; Donald E Thornton; Howard A Fine
Journal:  J Clin Oncol       Date:  2010-02-01       Impact factor: 44.544

Review 8.  The biology of VEGF and its receptors.

Authors:  Napoleone Ferrara; Hans-Peter Gerber; Jennifer LeCouter
Journal:  Nat Med       Date:  2003-06       Impact factor: 53.440

Review 9.  Antiangiogenic therapy in malignant glioma: promise and challenge.

Authors:  Sith Sathornsumetee; Jeremy N Rich
Journal:  Curr Pharm Des       Date:  2007       Impact factor: 3.116

10.  Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma.

Authors:  Teri N Kreisl; Lyndon Kim; Kraig Moore; Paul Duic; Cheryl Royce; Irene Stroud; Nancy Garren; Megan Mackey; John A Butman; Kevin Camphausen; John Park; Paul S Albert; Howard A Fine
Journal:  J Clin Oncol       Date:  2008-12-29       Impact factor: 44.544
View more
  1 in total

1.  Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.

Authors:  Orin Bloch; Andrew T Parsa
Journal:  Neuro Oncol       Date:  2014-04-10       Impact factor: 12.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.